Researchers say U.S. policymakers should look to Germany’s drug purchasing model to try and better align cancer drug prices with their clinical benefits, according to a STAT Pharmalot article.
According to the article, Germany’s model ultimately led to a 25 percent drop in prices one year post-launch.
The researchers’ recommendation came on the heels of an analysis involving 57 cancer drugs launched in Germany between 2002-2017.
To read the full article on STAT, click here. (Paid subscription required)